Key facts
- Aescolab’s last known valuation is $36.3M (Nov 2025).
- It has raised $6.3M; the latest was Early Stage VC in Nov 2025.
- Notable investors include Kring.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Aescolab
- ·The full record, as it builds
Funding rounds
No funding rounds for Aescolab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aescolab
Provider of blood analyses and personalized lifestyle recommendations intended to empower individuals to identify the underlying causes of their health issues and regain control of their well-being. The company offers quality blood analyses of over 70 biomarkers, including automated medicine interpretation of results and personalized treatment recommendations, enabling customers to gain clarity on their energy levels and identify the root causes of fatigue symptoms, ultimately leading to improved health and well-being.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2024
- Employees
- 10
- Website
- aescolab.de/
- Ownership
- Privately Held (backing)
Aescolab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aescolab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aescolab in its N-PORT filings yet. We sweep new filings monthly.